Jadelle (Levonorgestrel)

Levonorgestrel binds to progesterone receptors, suppressing the luteinising hormone surge and preventing ovulation. It also thickens cervical mucus and modifies the endometrial lining, creating conditions that hinder sperm movement and implantation, thereby reducing the chance of pregnancy.

The dosing regimen for Jadelle is determined by a qualified prescriber. Typically, two rods are inserted subcutaneously, each containing a fixed amount of levonorgestrel that releases hormone continuously for several years. The exact number and placement are set by the healthcare professional.

Jadelle is intended for use in women who are not pregnant. If pregnancy occurs, the implant should be removed promptly. Limited data exist on its safety during breastfeeding, but most guidelines advise that women can continue breastfeeding while using the implant, as systemic exposure is low.

To order Jadelle, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with oral contraceptive pills, Jadelle offers a longer duration of action (up to five years) and eliminates the need for daily adherence. Unlike injectable progestins, it provides a steady, low‑dose release without the peaks and troughs associated with periodic injections.

Jadelle should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the implants from moisture, direct sunlight and extreme temperature fluctuations to maintain product integrity until the time of insertion.

A trained healthcare professional inserts two Jadelle rods subcutaneously, usually in the inner side of the upper arm. The procedure is performed under aseptic conditions, and the insertion sites are covered with a small dressing after placement.

Serious risks, though rare, include ectopic pregnancy, severe allergic reactions, infection at the insertion site, pelvic inflammatory disease, and thromboembolic events such as deep‑vein thrombosis. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

Jadelle is contraindicated in women with a known or suspected pregnancy, active breast cancer, unexplained vaginal bleeding, severe liver disease, or a history of thromboembolic disorders. It should also be avoided in individuals with hypersensitivity to levonorgestrel or any component of the implant.